169 related articles for article (PubMed ID: 10709996)
41. Probing the specificity of cysteine proteinases at subsites remote from the active site: analysis of P4, P3, P2' and P3' variations in extended substrates.
Portaro FC; Santos AB; Cezari MH; Juliano MA; Juliano L; Carmona E
Biochem J; 2000 Apr; 347 Pt 1(Pt 1):123-9. PubMed ID: 10727410
[TBL] [Abstract][Full Text] [Related]
42. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
[TBL] [Abstract][Full Text] [Related]
43. Innovative workflow for the identification of cathepsin K cleavage sites in type I collagen.
Demeuse J; Massonnet P; Schoumacher M; Grifnée E; Huyghebaert L; Dubrowski T; Peeters S; Le Goff C; Cavalier E
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Aug; 1228():123864. PubMed ID: 37634391
[TBL] [Abstract][Full Text] [Related]
44. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones.
Xia L; Kilb J; Wex H; Li Z; Lipyansky A; Breuil V; Stein L; Palmer JT; Dempster DW; Brömme D
Biol Chem; 1999 Jun; 380(6):679-87. PubMed ID: 10430032
[TBL] [Abstract][Full Text] [Related]
45. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2011 Dec; 49(6):1351-6. PubMed ID: 21982869
[TBL] [Abstract][Full Text] [Related]
46. Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity.
Lecaille F; Choe Y; Brandt W; Li Z; Craik CS; Brömme D
Biochemistry; 2002 Jul; 41(26):8447-54. PubMed ID: 12081494
[TBL] [Abstract][Full Text] [Related]
47. Zinc Inhibits Collagenolysis by Cathepsin K and Matrix Metalloproteinases in Demineralized Dentin Matrix.
Altinci P; Seseogullari-Dirihan R; Can G; Pashley D; Tezvergil-Mutluay A
Caries Res; 2017; 51(6):576-581. PubMed ID: 29024928
[TBL] [Abstract][Full Text] [Related]
48. Regulation and enzymatic basis of bone resorption by human osteoclasts.
Fuller K; Kirstein B; Chambers TJ
Clin Sci (Lond); 2007 Jun; 112(11):567-75. PubMed ID: 17241109
[TBL] [Abstract][Full Text] [Related]
49. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.
Dodds RA; James IE; Rieman D; Ahern R; Hwang SM; Connor JR; Thompson SD; Veber DF; Drake FH; Holmes S; Lark MW; Gowen M
J Bone Miner Res; 2001 Mar; 16(3):478-86. PubMed ID: 11277265
[TBL] [Abstract][Full Text] [Related]
50. Human cathepsin L, a papain-like collagenase without proline specificity.
Korenč M; Lenarčič B; Novinec M
FEBS J; 2015 Nov; 282(22):4328-40. PubMed ID: 26306868
[TBL] [Abstract][Full Text] [Related]
51. Preparation of active recombinant cathepsin K expressed in bacteria as inclusion body.
Hwang HS; Chung HS
Protein Expr Purif; 2002 Aug; 25(3):541-6. PubMed ID: 12182837
[TBL] [Abstract][Full Text] [Related]
52. Binding potency of peptide fragments of type 1 collagen cross-linked N-telopeptide measured by an enzyme-linked immunosorbant assay.
Lung FD; Chen CH; Chen HY; Liou CC; Liou YM
Protein Pept Lett; 2002 Oct; 9(5):451-7. PubMed ID: 12370034
[TBL] [Abstract][Full Text] [Related]
53. Cathepsin S cannibalism of cathepsin K as a mechanism to reduce type I collagen degradation.
Barry ZT; Platt MO
J Biol Chem; 2012 Aug; 287(33):27723-30. PubMed ID: 22730330
[TBL] [Abstract][Full Text] [Related]
54. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine.
Hanson DA; Weis MA; Bollen AM; Maslan SL; Singer FR; Eyre DR
J Bone Miner Res; 1992 Nov; 7(11):1251-8. PubMed ID: 1466251
[TBL] [Abstract][Full Text] [Related]
55. Urinary excretion of cross-linked N-telopeptides of type 1 collagen to assess bone resorption in infants from birth to 1 year of age.
Lapillonne A; Travers R; DiMaio M; Salle BL; Glorieux FH
Pediatrics; 2002 Jul; 110(1 Pt 1):105-9. PubMed ID: 12093954
[TBL] [Abstract][Full Text] [Related]
56. A cytochemical assay for osteoclast cathepsin K activity.
Dodds RA
Cell Biochem Funct; 2003 Sep; 21(3):231-4. PubMed ID: 12910475
[TBL] [Abstract][Full Text] [Related]
57. Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice.
Zenger S; Hollberg K; Ljusberg J; Norgård M; Ek-Rylander B; Kiviranta R; Andersson G
Bone; 2007 Nov; 41(5):820-32. PubMed ID: 17765026
[TBL] [Abstract][Full Text] [Related]
58. Localisation and activity of cathepsins K and B in equine osteoclasts.
Gray AW; Davies ME; Jeffcott LB
Res Vet Sci; 2002 Apr; 72(2):95-103. PubMed ID: 12027589
[TBL] [Abstract][Full Text] [Related]
59. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
[TBL] [Abstract][Full Text] [Related]
60. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
Meier C; Meinhardt U; Greenfield JR; De Winter J; Nguyen TV; Dunstan CR; Seibel MJ
Clin Lab; 2006; 52(1-2):1-10. PubMed ID: 16506358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
